|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0011900,
umls-concept:C0013216,
umls-concept:C0034804,
umls-concept:C0205179,
umls-concept:C0220901,
umls-concept:C0441889,
umls-concept:C0600558,
umls-concept:C0918012,
umls-concept:C1514485,
umls-concept:C1517927,
umls-concept:C1522609,
umls-concept:C1554112
|
|
pubmed:issue |
3-4
|
|
pubmed:dateCreated |
2011-3-30
|
|
pubmed:abstractText |
Breast cancers expressing high levels of Ki-67, a nuclear marker of cell proliferation, are associated with worse outcome. Recent data from neoadjuvant studies indicate that a single measurement of the nuclear proliferation marker Ki-67 in breast carcinoma during neoadjuvant therapy is strongly predictive of long-term outcome. Secondly, recent literature data indicate that prognostic evaluation with Ki-67 may be better after pre-surgical therapy. A retrospective study from a prospectively maintained clinical database to compare the predictive and prognostic significance of biological markers, assessed before and after neoadjuvant chemotherapy, in locally advanced breast cancer, was performed.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1423-0232
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 S. Karger AG, Basel.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
79
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
255-61
|
|
pubmed:meshHeading |
pubmed-meshheading:21372600-Adolescent,
pubmed-meshheading:21372600-Adult,
pubmed-meshheading:21372600-Aged,
pubmed-meshheading:21372600-Aged, 80 and over,
pubmed-meshheading:21372600-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21372600-Breast Neoplasms,
pubmed-meshheading:21372600-Carcinoma, Ductal, Breast,
pubmed-meshheading:21372600-Carcinoma, Lobular,
pubmed-meshheading:21372600-Cell Proliferation,
pubmed-meshheading:21372600-Female,
pubmed-meshheading:21372600-Humans,
pubmed-meshheading:21372600-Immunoenzyme Techniques,
pubmed-meshheading:21372600-Middle Aged,
pubmed-meshheading:21372600-Neoadjuvant Therapy,
pubmed-meshheading:21372600-Prognosis,
pubmed-meshheading:21372600-Prospective Studies,
pubmed-meshheading:21372600-Receptor, erbB-2,
pubmed-meshheading:21372600-Receptors, Estrogen,
pubmed-meshheading:21372600-Receptors, Progesterone,
pubmed-meshheading:21372600-Retrospective Studies,
pubmed-meshheading:21372600-Survival Rate,
pubmed-meshheading:21372600-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
|
|
pubmed:affiliation |
S.C. Oncologia Medica C, Istituto Nazionale per Ricerca sul Cancro, ASL3 Genovese, Genova, Italy. loredana.miglietta@istge.it
|
|
pubmed:publicationType |
Journal Article
|
